Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. - Wikidata - awgldk - TriplyDB

Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.

Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.

http://www.wikidata.org/entity/Q35048908

about

CCAR1 promotes chromatin loading of androgen receptor (AR) transcription complex by stabilizing the association between AR and GATA2 Recurrent rearrangements in prostate cancer: causes and therapeutic potential Uncovering transcription factor modules using one- and three-dimensional analyses Mediator-dependent nuclear receptor function Emerging data on androgen receptor splice variants in prostate cancer The Mediator complex and transcription regulation An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts The link between androgen receptor splice variants and castration-resistant prostate cancer.MicroRNA as new tools for prostate cancer risk assessment and therapeutic intervention: results from clinical data set and patients' samples Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer.The role of GATA2 in lethal prostate cancer aggressiveness.Mediator and human disease Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer.Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells.Interrogating genomic and epigenomic data to understand prostate cancer Molecular pathways and targets in prostate cancer Genome-wide analysis uncovers high frequency, strong differential chromosomal interactions and their associated epigenetic patterns in E2-mediated gene regulation.Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women ERK2-mediated phosphorylation of transcriptional coactivator binding protein PIMT/NCoA6IP at Ser298 augments hepatic gluconeogenesis MED1 mediates androgen receptor splice variant induced gene expression in the absence of ligand Androgen receptor-driven chromatin looping in prostate cancer.Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells.Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF.The Med1 subunit of the mediator complex induces liver cell proliferation and is phosphorylated by AMP kinase.BAP18 coactivates androgen receptor action and promotes prostate cancer progression.Modeling a lethal prostate cancer variant with small-cell carcinoma features.Computational analysis reveals a correlation of exon-skipping events with splicing, transcription and epigenetic factors.Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer.Transcriptional network of androgen receptor in prostate cancer progression.Med1 subunit of the mediator complex in nuclear receptor-regulated energy metabolism, liver regeneration, and hepatocarcinogenesis Androgen receptor epigenetics.Identification of prognostic markers of high grade prostate cancer through an integrated bioinformatics approach.Investigation of potential molecular biomarkers and small molecule drugs for hepatocellular carcinoma transformed from cirrhosis.Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer.HEXIM1 plays a critical role in the inhibition of the androgen receptor by anti-androgens.MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer

P2860

Q24311817-DBD9D673-842A-4684-938C-E3C0215BFCC1 Q26851525-21F80358-F2B0-467D-BC4B-1A7225F3AEE0 Q26862955-611BAE53-EDB0-46D0-B4E4-4682B59CE60C Q26995848-876441D3-A77C-4DA1-924C-589FE06DEE8D Q28077830-239F05E8-8CBD-41E3-9AE8-81A56DF241B7 Q28299679-D667D67C-6029-481D-AD57-FDF013A7A7E5 Q28468447-32982BB9-D526-4FAE-8EC4-BFD796ED9239 Q30618562-BCF427C8-7AAA-4FB6-8D04-2385C4BA7864 Q30859743-B1352708-98C1-4D0B-9792-9C560325FDF8 Q30938412-7817CE89-D19F-408B-89C6-2D3F7799E89D Q33665345-A9F1B9EC-2547-42E0-AD51-72FFEC7E34E1 Q33675577-1E37AB8D-7CDB-4649-9CF3-9158C46F8DB4 Q33848134-A3369257-A090-4C22-BABB-4E5872A81E27 Q33909044-90454D3F-39E6-4D66-9F75-8D24C452D3F3 Q34042831-7930DD48-8311-4113-926A-CA1A1AA7B535 Q34077845-CC01712D-3A9D-473F-A351-D72B27D0E1CD Q34125866-728A60DD-837E-46C7-BF8A-72C00369AAB1 Q34365632-0DD28E14-4700-4E4F-B5A3-5A534924F0BE Q34569750-5BACD9C2-C529-413D-8BB5-25EAB1710021 Q34663140-01BAC15D-9221-40AF-870D-0B227CB32072 Q34737360-88A028EE-92FA-4BB3-912E-F6959A677097 Q35073182-7B7ABF61-0FDF-4840-ADEE-BE14622C96DA Q35238452-23E761B6-0067-4941-A459-EAA48F4A35E3 Q35589706-BDDA43CE-15B2-4FC8-AC24-E414CFD9F33B Q35871737-1B6EFEFD-F864-4ED0-9A5E-B50BA3C1411A Q36008102-3BDD0BA1-4889-46D0-A924-CC508A2499CB Q37201218-D367F7C1-1F6B-459F-8601-779EEC7F889E Q37294780-A6EAC5A6-9FAD-4637-8729-3009D8B5DFD8 Q37582049-30BE0594-8FE2-4723-888E-9924160800BF Q37631875-23DC1956-AC09-42E1-AF0C-C6225597138A Q37680421-10BA9400-5FF9-42C6-8527-9CC39D38D914 Q38100269-79451C30-C71A-4F14-848D-F6235F27A2B7 Q38209734-F5695E81-0E41-416E-9BD5-A1875C1BD41C Q38314940-864CD004-6E34-463D-BC8C-FF09581B16DD Q38429281-4F5F6D75-4234-4B43-91AF-1B815B2724A3 Q38445536-9CE1F2A1-B4BD-4037-8A89-559A7256E953 Q38835027-A87F43E0-9ADC-473F-85BC-D0874CCFEE3B Q38993411-3C84A534-B82C-40C6-9CFA-0EEC147421E0 Q39139064-905656AD-DD09-44EF-8862-FA1918109EA8 Q39164084-E220F13D-64B8-4E09-AF99-406BD357ED56

P2860

Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth.

http://www.wikidata.org/entity/Q35048908

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@ast

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@en

type

label

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@ast

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@en

prefLabel

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@ast

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@en

P1433

Q35048908-B3E49DFF-6207-4FBA-8DCD-03E2BF6C9F63

P1476

Q35048908-43EC1634-5B1F-4312-9007-E06E822DB69F

P2093

Q35048908-456F276C-F821-4D59-A9BA-1E93D34318AC

Q35048908-52B0F212-38F0-48E5-8CCC-4585235C8056

Q35048908-7E2E9D6E-6B2D-4539-AF19-8CF92F562455

Q35048908-A08CC31B-B293-441B-B605-D8109475A1A0

Q35048908-B5A690C3-48AD-470F-A7BA-5AA4E970F02B

Q35048908-ED649035-D443-4137-8889-429B317271F3

Q35048908-FB1751B2-D815-4BC5-A759-8BB754207841

P2860

Q35048908-0273C683-6069-4DA4-8276-ED747DF5DCA1

Q35048908-0409DB31-473F-4C07-ABD5-2513C24A122C

Q35048908-0BA56F30-BDAA-455B-AE03-0E43354C338F

Q35048908-0E65BFE1-21B1-4DF7-89C6-51037BF76A3E

Q35048908-195657A9-AF14-475D-9BF6-961F8633463B

Q35048908-1A69C608-234E-4681-8D8C-2BFF7B06ED2A

Q35048908-1A7FB16B-DC0F-4AB3-B6E3-944C22FF303A

Q35048908-1B3C7467-3D69-415F-B6E5-D87072E10338

Q35048908-1EEF8FED-92AF-4EED-868A-C45417459307

Q35048908-26CFD97E-1176-4F1C-9635-2B7874A61606

P304

Q35048908-7E77E502-F04D-44FA-AF98-086624481477

P31

Q35048908-9D413B97-3DC2-45B5-BA28-DD99C53073B7

P356

Q35048908-F98C9EA9-26A4-43C3-A4F5-1B19C5EA8792

P407

Q35048908-ED9DE58B-8DDF-42EF-B82D-EAC7BAAEBEAB

P433

Q35048908-275F312C-B985-42B3-97DF-AE12644D87CE

P478

Q35048908-605604E3-9D26-4872-8F27-F06D0C8DADE6

P577

Q35048908-F4FCFE84-6742-4144-92FE-2D41216FC8F4

P5875

Q35048908-95381899-EAEF-44E4-B7BE-A7E54E9F6559

P698

Q35048908-0608D7CD-7F18-4214-ADC6-DA65342A6CCD

P932

Q35048908-DDD6571A-FC70-42F3-AB0D-E02DB967BC01

P356

P1433

The EMBO Journal

P1476

Phospho-MED1-enhanced UBE2C lo ...... istant prostate cancer growth.

@en

P2093

Anna Rorick

http://www.w3.org/2001/XMLSchema#string

Chunpeng Zhang

http://www.w3.org/2001/XMLSchema#string

Dayong Wu

http://www.w3.org/2001/XMLSchema#string

Hongyan Chen

http://www.w3.org/2001/XMLSchema#string

Qianben Wang

http://www.w3.org/2001/XMLSchema#string

Xiaoting Zhang

http://www.w3.org/2001/XMLSchema#string

Zhong Chen

http://www.w3.org/2001/XMLSchema#string

P2860

BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources.

Activation of TRAP/mediator subunit TRAP220/Med1 is regulated by mitogen-activated protein kinase-dependent phosphorylation

A coregulatory role for the TRAP-mediator complex in androgen receptor-mediated gene expression

An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression

MED1 phosphorylation promotes its association with mediator: implications for nuclear receptor signaling

Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo.

Genome-wide mapping of DNase hypersensitive sites using massively parallel signature sequencing (MPSS)

Mediator and cohesin connect gene expression and chromatin architecture

FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription

Combinatorial patterns of histone acetylations and methylations in the human genome

P304

2405-2419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/EMBOJ.2011.154

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2011-05-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51111230

http://www.w3.org/2001/XMLSchema#string

P698

21556051

http://www.w3.org/2001/XMLSchema#string

P932

3116285

http://www.w3.org/2001/XMLSchema#string